Ketamine Therapy for ALS: Complete Guide

It's late. The BiPAP is running, the suction equipment is charged, and sleep still won't come. Maybe you're living with early-stage ALS and the depression feels like a second diagnosis no one prepared you for. Maybe you're the caregiver, still awake after medications and feeding and secretion management, wondering whether anything can touch the heaviness settling into both of you.

Standard antidepressants help some people with ALS. But they take weeks to work, and controlled clinical trials of antidepressants specifically in people with ALS appear to be lacking. The entire psychiatric treatment approach for ALS runs on expert consensus, not trial evidence. That context matters when you're weighing options.

The bottom line: Animal research was promising enough that the FDA granted ketamine Orphan Drug Designation for ALS in 2021, and a Phase 2 trial at the University of Missouri is now testing whether IV ketamine can slow disease progression in humans. But no completed human data yet support that use, and Phase 3 trials aren't planned until 2026. What's available now, off-label, is ketamine for the depression that affects roughly one in three people with ALS and often resists standard treatments. Safety for either use depends heavily on your specific ALS profile.

What Is ALS?

Amyotrophic lateral sclerosis (ALS) affects an estimated 35,000 Americans, with roughly 5,000 new diagnoses each year.

Beyond the physical toll, ALS brings psychiatric symptoms that often become the hardest part of daily life. Depression, anxiety, and pseudobulbar affect (uncontrollable laughing or crying unrelated to actual emotions) are common. These symptoms have biological roots, and they deserve treatment in their own right.

Traditional Treatments for ALS Depression and Their Limitations

When depression or anxiety appears, clinicians often start with SSRIs like sertraline or citalopram, sometimes adding older antidepressants like amitriptyline. None of these medications have been formally tested in people with ALS, and SSRIs take four to six weeks to reach full effect. When time matters this much, six weeks can feel like an unbearable wait.

Clinicians sometimes prescribe benzodiazepines short-term for anxiety, but these drugs worsen breathing in people who already have respiratory weakness. Clinicians need to determine whether anxiety is actually caused by breathing difficulty before prescribing them.

One condition deserves special attention. Pseudobulbar affect, with pooled prevalence of 38.5% in ALS patients across studies, causes emotional outbursts that look like depression but aren't. It has its own FDA-approved treatment, Nuedexta, which was tested specifically in ALS and multiple sclerosis patients. If uncontrollable crying or laughing is the primary symptom, that's the conversation to have with your neurologist first.

How Does Ketamine Therapy for ALS Work?

Ketamine works differently from SSRIs. Instead of slowly changing serotonin over weeks, it acts on NMDA receptors, brain signaling pathways involved in learning and memory. It sets off a chain reaction involving glutamate, a brain chemical, and prompts the release of BDNF, a protein that helps neurons form new connections. The result is an antidepressant effect that can begin within hours rather than weeks.

That speed matters for people with ALS. When you're managing a progressive disease, six weeks of waiting for a medication to maybe work is a different kind of bet.

Ketamine also promotes neuroplasticity, which helps the brain form new pathways. Both ketamine and riluzole (an FDA-approved ALS drug) share some NMDA activity, which has fueled speculation about whether ketamine might affect ALS progression itself.

What Does the Research Show?

Two parallel research stories matter here, and they're often confused.

1. Disease-modification research

Preclinical work at the University of Kansas Medical Center, led by neurologist Dr. Richard Barohn and colleagues, found that ketamine preserved muscle function and extended survival in animal models of ALS when administered during early muscle decline. Based on this research, the FDA granted ketamine Orphan Drug status for ALS in 2021. PharmaTher Holdings, which licensed the work from Kansas, secured a US patent for this use in June 2025. An FDA-approved Phase 2 trial at the University of Missouri, with Dr. Barohn as principal investigator, is evaluating IV ketamine in 36 ALS patients across three dose cohorts. Endpoints include neurofilament light chain (a biomarker of motor neuron damage), the ALS Functional Rating Scale, depression scoring, manual muscle testing, and forced vital capacity. Phase 3 trials are not planned until 2026, and no completed human data yet support ketamine as a disease-modifying treatment.

2. Depression research

Separately, ketamine has established benefit for treatment-resistant depression in studied populations. Antidepressant effects often appear within hours rather than weeks. Evidence in older adults and people with cognitive impairment remains preliminary and mixed. No completed depression trials specific to ALS exist yet, though depression scoring is a secondary endpoint in the Phase 2 disease-modification trial.

In practical terms, research into ketamine as a disease-modifying ALS treatment is active and FDA-supported, but it isn't yet an available treatment outside of clinical trials.

The off-label option that does exist now addresses the depression and anxiety that often accompany ALS. These are different products with different protocols and different evidence bases: IV ketamine in a research setting versus sublingual ketamine at home for off-label psychiatric use. Innerwell's program offers the latter.

If you're interested specifically in the disease-modification trial, ask your neurologist or search ClinicalTrials.gov for the University of Missouri program.

What Are the Risks of Ketamine Therapy for ALS?

Common Side Effects

Common side effects are short-lived: a dissociative sensation, mild nausea, dizziness, or temporary blood pressure elevation. These typically resolve within two hours. But ALS introduces specific risks that don't apply to most other populations.

ALS-Specific Concerns

The secretion problem is the most serious concern. Ketamine increases oral secretions, which is a minor nuisance for most people. For someone with bulbar ALS (the form that affects speaking, swallowing, and saliva control), the combination creates a real aspiration risk. People with bulbar involvement already can't clear secretions effectively and may have a reduced cough reflex.

Respiratory reserve also matters. Ketamine preserves respiratory drive better than benzodiazepines or opioids, but people with ALS whose forced vital capacity is below 50% of predicted have markedly reduced reserve. That threshold means a breathing test shows significantly reduced lung capacity, and neurology guidelines recommend that sedating agents be used with extra caution in this group.

The FDA warns that combining opioids with benzodiazepines or other CNS depressants can cause extreme sleepiness, respiratory depression, coma, and death.

ALS is not listed as a contraindication on FDA ketamine labeling. A 2024 Cleveland Clinic review lists ketamine among sedation options for neuromuscular disease patients without flagging it as contraindicated. But the risk profile changes significantly with bulbar involvement, reduced lung capacity, rapid IV administration, or concurrent CNS depressant use.

When Ketamine May Not Be Appropriate

Ketamine may not be appropriate if you have:

• Bulbar ALS with impaired swallowing or cough reflex
• Forced vital capacity at or below 50% of predicted
• Uncontrolled high blood pressure or unstable heart disease
• Active use of opioids or benzodiazepines without medical coordination
• A personal or family history of psychosis

If any of these apply, raise them openly during your evaluation so Innerwell's clinical team can assess whether treatment is feasible.

How Innerwell's Ketamine Therapy Approach Works for ALS

You don't have to navigate this alone. Innerwell's at-home ketamine therapy program helps you find relief from treatment-resistant symptoms with clinical oversight, licensed psychotherapist guidance, and scheduling that adapts to caregiving routines. For ALS, every phase requires adaptation.

The process:

1. Clinical evaluation. Your assessment includes cognitive screening, a review of breathing and heart health, medication interaction analysis, and a conversation about bulbar involvement and swallowing status. When respiratory or bulbar issues are present, Innerwell coordinates with your neurologist and palliative care team.
2. Secure at-home medication delivery. Sublingual ketamine tablets arrive with conservative dosing protocols and clear instructions for both patient and caregiver. For people with ALS, this phase includes fall-risk precautions and an assessment of whether sublingual administration is still safe and practical. ALS can eventually make sublingual routes unsafe due to dysphagia, or trouble swallowing, which affects most patients over the disease course.
   Guided preparation and integration therapy. Licensed therapists guide intention-setting before each session and help process what comes up afterward. For ALS, integration involves caregivers directly and adapts communication to speech or motor limitations.
3. Ongoing monitoring and dosage adjustment. Mood tracking, blood pressure, respiratory status, and caregiver feedback all feed into treatment adjustments.

Read our guide on how to prepare for ketamine therapy.

Pricing

With insurance, Innerwell's ketamine programs run $54 to $75 per session, compared to $400 to $800 per session at IV ketamine clinics. Self-pay options range from $83 to $125 per session. Insurance partnerships currently extend to over 22 million people in California and New York.

Clinical Outcomes

Across the general patient population, Innerwell members see a 69% reduction in depression symptoms and a 60% reduction in anxiety symptoms after 10 weeks. 87% see improvement within four weeks. Average patient rating: 4.7 out of 5.

Is Ketamine Therapy for ALS Right for Me?

If ALS-related depression or anxiety hasn't responded to SSRIs, ketamine may offer relief where other options have fallen short, as long as the bulbar, respiratory, and medication risks outlined above are manageable.

You're likely a good fit if depression persists despite standard antidepressants and you have reliable caregiver support before, during, and after sessions.

Even when appropriate, ketamine works best alongside existing ALS care, not instead of it. Riluzole, multidisciplinary team management, and palliative care remain the foundation. Ketamine addresses one specific piece: the depression and anxiety that erode quality of life.

Every Innerwell patient begins with a thorough evaluation that accounts for ALS-specific risks. Honest answers about your respiratory status, medications, and bulbar symptoms help the clinical team protect you and provide the clearest picture of whether treatment can help.

A Note for Caregivers

Caring for someone with ALS exacts its own toll. In one comparative study of ALS caregivers, 20% had depression and 48% reported high caregiver burden. A more recent multi-method study found roughly 70% reporting significant caregiver burden. Research published in Neurology found that over nine months, ALS patients remained in the not-depressed range while caregiver distress increased.

If you're an ALS caregiver experiencing depression, you don't face the respiratory or swallowing concerns that apply to people with ALS. Ketamine therapy for treatment-resistant depression has a growing evidence base, and Innerwell's at-home program runs the same way for caregivers as for anyone else seeking it. You deserve treatment for your own mental health, not just your loved one's.

Try Ketamine Therapy With Innerwell

When standard antidepressants aren't enough for the depression that accompanies ALS, ketamine offers a different mechanism. People with ALS, and the people caring for them, deserve access to honest information about their options, not false hope and not premature dismissal.

Take our free assessment to see if ketamine therapy might work for your situation.

Frequently Asked Questions About Ketamine Therapy for ALS

Can ketamine slow ALS progression?

Not yet established. Animal research led the FDA to grant Orphan Drug Designation in 2021, and a Phase 2 trial is currently testing the question in humans, with Phase 3 not planned until 2026. No completed human data yet support disease modification. What's available now, off-label, is ketamine for the depression and anxiety that accompany ALS, which is what Innerwell's program addresses.

Will ketamine interfere with my current ALS medications?

Ketamine and riluzole both interact with NMDA receptor pathways, but no specific interaction has been formally documented. Edaravone, oral edaravone, and tofersen don't have known ketamine interactions. The bigger concern is concurrent use of opioids, benzodiazepines, or other CNS depressants, which significantly increases sedation and respiratory risks. Innerwell's clinical evaluation includes a full medication review and coordinates with your neurologist when needed.

How long does it take for ketamine therapy to work?

Ketamine can produce antidepressant effects within hours to days. For someone with ALS, that speed is part of what makes ketamine worth considering when standard antidepressants haven't worked.

Is ketamine therapy for ALS legal?

Yes. Ketamine is an FDA-approved Schedule III medication, originally approved as an anesthetic, that licensed clinicians can prescribe off-label for conditions such as depression and anxiety. It is not FDA-approved for the treatment of any psychiatric disorder, so treatment represents an off-label clinical decision made between you and your provider.

Is ketamine therapy for ALS covered by insurance?

Because this use is off-label, insurance coverage varies. Innerwell partners with insurance plans in California and New York, where eligible patients pay $54 to $75 per session. For others, self-pay pricing and financing options keep treatment significantly more accessible than the $400 to $800 per session typical at IV clinics. The financial side is a legitimate concern worth discussing during your evaluation.